MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Outlook Arena
- Jun 24, 2003 - Dr Reddy’s Lab: R&D driving growth
Dr Reddy’s Lab: R&D driving growth
Continuing with our series of articles evaluating the business structure of major pharma companies, consider Dr. Reddy’s Laboratories (DRL) in this article. DRL is one of India’s fastest growing pharma companies. The foresightedness in recognizing generics opportunity in developed markets and initiatives like spearheading basic pharma research in the country demonstrates management vision. The company is fast emerging as a speciality pharma company. DRL’s new drug discovery research initiatives have resulted in the company having the most enviable NCE pipeline in the domestic industry.
| Region | FY01 | FY02 | FY03 |
| India | 54 | 39 | 36 |
| USA | 15 | 34 | 32 |
| Europe | 2 | 2 | 8 |
| Russia | 7 | 8 | 9 |
| RoW | 22 | 17 | 15 |
DRL derives 64% of its revenues from exports. There has been a sharp increase in contribution from the US. This has been possible due to the company’s policy of challenging existing drug patents in USA through Para 4 ANDA filings and launching generic version of the same at a lower cost. This has helped DRL reduce its dependence on the Indian market, which is characterised by intense competition and lack of pricing power. With the acquisition of BMS and Meridian in FY03 in the UK, DRL has further consolidated its presence in Europe.
| FY01 | FY02 | FY03 | |
| Bulk drugs | 44 | 31 | 35 |
| Branded formulation | 50 | 36 | 38 |
| Generics | 3 | 27 | 24 |
| Others | 3 | 6 | 3 |
Branded formulations contributed 38% of DRL’s total revenues in FY03, with the domestic market contributing 24% of sales. The company has a major presence in the pain management, gastro intestinal and cardiovascular therapeutic segments. For many years, ‘Nise’ had been DRL’s power brand contributing 15% of domestic branded sales. However, with safety concerns being raised, the company has decided to discontinue production of this brand.
| FY01 | FY02 | FY03 | |
| Revenues (Rs m) | 9,127 | 15,211 | 15,136 |
| PAT (Rs m) | 1,445 | 4,597 | 3,921 |
| OPM (%) | 26.6 | 31.5 | 28.3 |
| NPM (%) | 15.8 | 30.2 | 25.9 |
| R & D (% of Revenues) | 4.6 | 6.4 | 7.6 |
DRL has been able to successfully challenge existing patents due to the company’s increased thrust on research and development. R&D investments as a percentage of net sales have gone up from 4.6% in FY01 to 7.6% in FY03. In FY03, DRL has filed 14 Abbreviated New Drug Applications (ANDAs) of which 10 were Para 4 filings. Thus, the total number of ANDAs pending for US FDA approval stands at 23. Recently, DRL had won a patent case for the launch of ‘Amlodipine Maleate’, a generic version of Pfizer’s patented drug ‘Norvasc’. Pfizer has appealed against the order, and the case in pending with the higher courts. If DRL wins the case, it will be able to generate profits to the tune of US$ 98 m, which is higher than its FY03 profits of US$ 74m.
More on pharma R&D
DRL has also started developing New Chemical Entities (NCE), which is a molecule that could after clinical trials be used for curing a disease. The company licenses out the NCEs to foreign companies for conducting clinical trails and receives upfront and milestone payments for the same. In FY02, DRL received upfront and milestone payments (Rs 389 m) in respect of two NCEs DRF-2725 and DRF-4158 licensed to Novo Nordisk and Novartis respectively.
| Therapeutic segment | Stage of development | ||
| Pre clinical stage | Clinical trials | ||
| Phase 1 | Phase 2 | ||
| Diabetes | - | - | DRF 2593 |
| Metabolic disorder | DRF 4832, DRF 10945 | - | - |
| Cancer | DRF1644 | DRF 1042 | - |
| Bacterial infection | DRF 11057 | - | - |
However, DRL’s research has had its share of failures as well. Clinical trials in respect of two of the three molecules licensed have been discontinued. Novo Nordisk terminated clinical trials for the NCE DRF-2725, while Novartis AG discontinued further development of DRF-4158. This has come as a major setback to DRL, as it would not be receiving any further milestone payments in respect of these two molecules. NCE research and new drug development being a high-risk activity, DRL could show volatility in performance.
Apart from R&D failure risks, with DRL aggressively challenging existing patents, the legal expenses of the company could record a sharp rise. Moreover, the discontinuance of its leading brand ‘Nise’ could have a marginal effect on the performance of the company.
The stock currently trades at Rs 1,058 implying a P/E multiple of 16.6x annualised 1QFY04 earnings. DRL’s strategy of increasing R&D expenditure indicates the company’s preparedness to face the future. In the near term, due to the high-risk ventures that DRL has undertaken, the performance of the company may be affected. However, for the long term, prospects of the company are bright.
More Views on News
Sorry! There are no related views on news for this company/sector.
Most Popular
A Critical Update on the Market (Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy (Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers (Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
MoreOUR TOP 5 IDEAS
- India's Revival: A Once-in-a-generation Wealth Making Opportunity
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
RANBAXY LAB SHARE PRICE
Apr 1, 2015 (Close)
TRACK RANBAXY LAB
- Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "Dr Reddy’s Lab: R&D driving growth ". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!